U.S. markets open in 5 hours 55 minutes
  • S&P Futures

    4,417.75
    +28.25 (+0.64%)
     
  • Dow Futures

    35,039.00
    +207.00 (+0.59%)
     
  • Nasdaq Futures

    15,042.25
    +86.50 (+0.58%)
     
  • Russell 2000 Futures

    2,247.70
    +26.10 (+1.17%)
     
  • Crude Oil

    73.35
    -0.60 (-0.81%)
     
  • Gold

    1,809.30
    -7.90 (-0.43%)
     
  • Silver

    25.52
    -0.03 (-0.11%)
     
  • EUR/USD

    1.1888
    +0.0013 (+0.11%)
     
  • 10-Yr Bond

    1.2390
    0.0000 (0.00%)
     
  • Vix

    18.15
    +0.45 (+2.54%)
     
  • GBP/USD

    1.3929
    +0.0022 (+0.16%)
     
  • USD/JPY

    109.7200
    +0.1050 (+0.10%)
     
  • BTC-USD

    40,197.50
    -1,584.82 (-3.79%)
     
  • CMC Crypto 200

    977.99
    +28.09 (+2.96%)
     
  • FTSE 100

    7,102.33
    +70.03 (+1.00%)
     
  • Nikkei 225

    27,781.02
    +497.43 (+1.82%)
     

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

·2 min read

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate events on June 16, 2021 at 8:30 AM Eastern Time.

The conference call may be accessed by dialing 877-451-6152 (U.S.) or 201-389-0879 (International) and referencing conference ID: 13720525. A live webcast will be available on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section. An archived replay of the webcast will be available for 90 days.

About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class NDA-stage lead asset plinabulin, a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), is a “pipeline in a drug.” It is filed for approval with Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study (Dublin-3) to test an anti-cancer benefit with an overall survival primary endpoint in non-small cell lung cancer (NSCLC). Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com

Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
darren@lifescicomms.com